Werewolf Therapeutics, Inc.
Clinical trials sponsored by Werewolf Therapeutics, Inc., explained in plain language.
-
New drug WTX-330 aims to boost immune system against tough cancers
Disease control OngoingThis study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The main goals are to find safe dose levels and see if the drug can shrink tumors. Researchers will also mea…
Phase: PHASE1, PHASE2 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-phase study tests a new drug called WTX-124, given alone or with another drug (pembrolizumab), in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also looking at whe…
Phase: PHASE1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated May 04, 2026 16:30 UTC